APA (7th ed.) Citation

P, G., BJ, M., D, P., M, R., G, F., S, G., . . . M, M. (2019). Immune Checkpoint Inhibitors as Switch or Continuation Maintenance Therapy in Solid Tumors: Rationale and Current State. Targeted oncology, 14(5), 505. https://doi.org/10.1007/s11523-019-00665-1

Chicago Style (17th ed.) Citation

P, Grivas, Monk BJ, Petrylak D, Reck M, Foley G, Guenther S, Hennessy D, Makris C, and Moehler M. "Immune Checkpoint Inhibitors as Switch or Continuation Maintenance Therapy in Solid Tumors: Rationale and Current State." Targeted Oncology 14, no. 5 (2019): 505. https://doi.org/10.1007/s11523-019-00665-1.

MLA (9th ed.) Citation

P, Grivas, et al. "Immune Checkpoint Inhibitors as Switch or Continuation Maintenance Therapy in Solid Tumors: Rationale and Current State." Targeted Oncology, vol. 14, no. 5, 2019, p. 505, https://doi.org/10.1007/s11523-019-00665-1.